Table 5.
AEs.
| Items | Total | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|---|
| Total AEs, No. (%) | 91 (90.1) | 21 (20.8) | 29 (28.7) | 38 (37.6) | 3 (3.0) |
| Hematologic AEs, No. (%) | 91 (90.1) | 24 (23.8) | 27 (26.7) | 37 (36.6) | 3 (3.0) |
| Transaminase elevation, No. (%) | 61 (60.4) | 26 (25.7) | 18 (17.8) | 17 (16.8) | 0 (0.0) |
| Thrombocytopenia, No. (%) | 58 (57.4) | 24 (23.8) | 15 (14.9) | 17 (16.8) | 2 (2.0) |
| Hypoalbuminemia, No. (%) | 55 (54.5) | 35 (34.7) | 19 (18.8) | 1 (1.0) | 0 (0.0) |
| Hyperbilirubinemia, No. (%) | 48 (47.5) | 28 (27.7) | 16 (15.8) | 4 (4.0) | 0 (0.0) |
| Leukopenia, No. (%) | 43 (42.6) | 12 (11.9) | 25 (24.8) | 6 (5.9) | 0 (0.0) |
| Neutropenia, No. (%) | 41 (40.6) | 17 (16.8) | 12 (11.9) | 11 (10.9) | 1 (1.0) |
| Anemia, No. (%) | 40 (39.6) | 30 (29.7) | 9 (8.9) | 1 (1.0) | 0 (0.0) |
| Albuminuria, No. (%) | 27 (26.7) | 17 (16.8) | 8 (7.9) | 2 (2.0) | 0 (0.0) |
| Creatinine elevation, No. (%) | 3 (3.0) | 2 (2.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) |
| Non-hematologic AEs, No. (%) | 29 (28.7) | 16 (15.8) | 10 (9.9) | 2 (2.0) | 0 (0.0) |
| Immune-related AEs | 8 (7.9) | 5 (5.0) | 2 (2.0) | 1 (1.0) | 0 (0.0) |
| Rash, No. (%) | 7 (6.9) | 6 (5.9) | 1 (1.0) | 0 (0.0) | 0 (0.0) |
| RCCEP, No. (%) | 6 (5.9) | 3 (3.0) | 3 (3.0) | 0 (0.0) | 0 (0.0) |
| Fever, No. (%) | 5 (5.0) | 4 (4.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) |
| Pain, No. (%) | 5 (5.0) | 4 (4.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) |
| Fatigue, No. (%) | 5 (5.0) | 3 (3.0) | 1 (1.0) | 1 (1.0) | 0 (0.0) |
| Loss of appetite, No. (%) | 4 (4.0) | 3 (3.0) | 0 (0.0) | 1 (1.0) | 0 (0.0) |
| Hand foot syndrome, No. (%) | 1 (1.0) | 0 (0.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) |
| Nausea and vomiting, No. (%) | 1 (1.0) | 0 (0.0) | 1 (1.0) | 0 (0.0) | 0 (0.0) |
AEs, adverse events; RCCEP, reactive cutaneous capillary endothelial proliferation.